JP2013525305A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013525305A5 JP2013525305A5 JP2013505156A JP2013505156A JP2013525305A5 JP 2013525305 A5 JP2013525305 A5 JP 2013525305A5 JP 2013505156 A JP2013505156 A JP 2013505156A JP 2013505156 A JP2013505156 A JP 2013505156A JP 2013525305 A5 JP2013525305 A5 JP 2013525305A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- multimeric ligand
- subject
- region
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003446 ligand Substances 0.000 claims description 254
- 102000037865 fusion proteins Human genes 0.000 claims description 132
- 108020001507 fusion proteins Proteins 0.000 claims description 132
- 101150013553 CD40 gene Proteins 0.000 claims description 110
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 110
- 239000002773 nucleotide Substances 0.000 claims description 110
- 125000003729 nucleotide group Chemical group 0.000 claims description 110
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 107
- 206010060862 Prostate cancer Diseases 0.000 claims description 106
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 100
- 102000036639 antigens Human genes 0.000 claims description 92
- 108091007433 antigens Proteins 0.000 claims description 92
- 239000000427 antigen Substances 0.000 claims description 89
- 108091033319 polynucleotide Proteins 0.000 claims description 61
- 102000040430 polynucleotide Human genes 0.000 claims description 61
- 239000002157 polynucleotide Substances 0.000 claims description 61
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 60
- 239000012528 membrane Substances 0.000 claims description 58
- 229920001184 polypeptide Polymers 0.000 claims description 58
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 58
- 230000008685 targeting Effects 0.000 claims description 58
- 206010028980 Neoplasm Diseases 0.000 claims description 57
- 230000001086 cytosolic effect Effects 0.000 claims description 56
- 239000000203 mixture Substances 0.000 claims description 39
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 35
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 35
- 230000005747 tumor angiogenesis Effects 0.000 claims description 29
- 239000013598 vector Substances 0.000 claims description 27
- 239000002246 antineoplastic agent Substances 0.000 claims description 25
- 229940127089 cytotoxic agent Drugs 0.000 claims description 25
- 102000039446 nucleic acids Human genes 0.000 claims description 25
- 108020004707 nucleic acids Proteins 0.000 claims description 25
- 150000007523 nucleic acids Chemical class 0.000 claims description 25
- 230000028993 immune response Effects 0.000 claims description 17
- 238000002512 chemotherapy Methods 0.000 claims description 12
- 230000035945 sensitivity Effects 0.000 claims description 12
- 230000004044 response Effects 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 7
- 210000002307 prostate Anatomy 0.000 claims description 7
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 claims description 6
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 claims description 6
- 210000000988 bone and bone Anatomy 0.000 claims description 4
- 230000003111 delayed effect Effects 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 210000001165 lymph node Anatomy 0.000 claims description 4
- 230000001394 metastastic effect Effects 0.000 claims description 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 3
- 229960003668 docetaxel Drugs 0.000 claims description 3
- 102000001493 Cyclophilins Human genes 0.000 claims description 2
- 108010068682 Cyclophilins Proteins 0.000 claims description 2
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 claims description 2
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 claims description 2
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 claims description 2
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 claims description 2
- 229940123237 Taxane Drugs 0.000 claims description 2
- 239000004098 Tetracycline Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 claims description 2
- 229960001573 cabazitaxel Drugs 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 210000004443 dendritic cell Anatomy 0.000 claims description 2
- 208000010658 metastatic prostate carcinoma Diseases 0.000 claims description 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 2
- 229960002180 tetracycline Drugs 0.000 claims description 2
- 229930101283 tetracycline Natural products 0.000 claims description 2
- 235000019364 tetracycline Nutrition 0.000 claims description 2
- 230000002463 transducing effect Effects 0.000 claims description 2
- 239000013066 combination product Substances 0.000 claims 11
- 229940127555 combination product Drugs 0.000 claims 11
- 241000701161 unidentified adenovirus Species 0.000 claims 6
- 230000035572 chemosensitivity Effects 0.000 claims 3
- 238000000034 method Methods 0.000 description 142
- 230000004614 tumor growth Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32512710P | 2010-04-16 | 2010-04-16 | |
| US61/325,127 | 2010-04-16 | ||
| US35176010P | 2010-06-04 | 2010-06-04 | |
| US61/351,760 | 2010-06-04 | ||
| US201161442582P | 2011-02-14 | 2011-02-14 | |
| US61/442,582 | 2011-02-14 | ||
| PCT/US2011/032572 WO2011130566A2 (en) | 2010-04-16 | 2011-04-14 | Method for treating solid tumors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016060361A Division JP2016117770A (ja) | 2010-04-16 | 2016-03-24 | 固形腫瘍を処置するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013525305A JP2013525305A (ja) | 2013-06-20 |
| JP2013525305A5 true JP2013525305A5 (OSRAM) | 2014-05-01 |
| JP5975983B2 JP5975983B2 (ja) | 2016-08-23 |
Family
ID=44799326
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013505156A Active JP5975983B2 (ja) | 2010-04-16 | 2011-04-14 | 固形腫瘍を処置するための方法 |
| JP2016060361A Withdrawn JP2016117770A (ja) | 2010-04-16 | 2016-03-24 | 固形腫瘍を処置するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016060361A Withdrawn JP2016117770A (ja) | 2010-04-16 | 2016-03-24 | 固形腫瘍を処置するための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20110287038A1 (OSRAM) |
| EP (1) | EP2558109A4 (OSRAM) |
| JP (2) | JP5975983B2 (OSRAM) |
| AU (1) | AU2011239569B2 (OSRAM) |
| CA (1) | CA2795947A1 (OSRAM) |
| WO (1) | WO2011130566A2 (OSRAM) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2933334B1 (en) | 2003-02-18 | 2019-09-18 | Baylor College of Medicine | Induced activation in dendritic cells |
| US8691210B2 (en) | 2006-10-19 | 2014-04-08 | David M Spencer | Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptors and adaptors thereof |
| ES2633470T3 (es) | 2008-09-22 | 2017-09-21 | Baylor College Of Medicine | Métodos y composiciones de generación de una respuesta inmune mediante la inducción de CD40 y adaptadores de receptores de reconocimiento de patrones |
| EA024186B1 (ru) | 2009-10-29 | 2016-08-31 | Авентис Фарма С.А. | Применение кабазитаксела в комбинации с преднизоном или преднизолоном для лечения рака простаты |
| WO2011146862A1 (en) | 2010-05-21 | 2011-11-24 | Bellicum Pharmaceuticals, Inc. | Methods for inducing selective apoptosis |
| AR089028A1 (es) | 2011-11-29 | 2014-07-23 | Genentech Inc | Composiciones y metodos para el analisis de cancer de prostata |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| US9434935B2 (en) | 2013-03-10 | 2016-09-06 | Bellicum Pharmaceuticals, Inc. | Modified caspase polypeptides and uses thereof |
| KR20150131218A (ko) | 2013-03-14 | 2015-11-24 | 벨리쿰 파마슈티컬스, 인크. | T 세포 증식의 제어 방법 |
| MX369709B (es) * | 2013-03-15 | 2019-11-19 | Univ Pennsylvania | Vacunación mejorada contra tirosinasa. |
| HK1220205A1 (zh) | 2013-03-15 | 2017-04-28 | Celgene Corporation | 修饰的t淋巴细胞 |
| US10155795B2 (en) | 2013-03-15 | 2018-12-18 | The Trustees Of The University Of Pennsylvania | Compositions comprising hypoxia inducible factor-1 alpha and methods of using the same |
| US9913882B2 (en) | 2013-06-05 | 2018-03-13 | Bellicum Pharmaceuticals, Inc. | Methods for inducing partial apoptosis using caspase polypeptides |
| JP6496472B2 (ja) * | 2013-07-03 | 2019-04-03 | 三菱重工機械システム株式会社 | 車載器、及びスプーフィング検知方法 |
| CN106132423B (zh) * | 2014-02-14 | 2020-07-31 | 贝里坤制药股份有限公司 | 用诱导型嵌合多肽活化t细胞的方法 |
| EP2940136A1 (en) * | 2014-04-30 | 2015-11-04 | QIAGEN GmbH | Method for isolating poly(A) nucleic acids |
| JP6868554B2 (ja) | 2014-09-02 | 2021-05-12 | ベリカム ファーマシューティカルズ， インコーポレイテッド | ＭｙＤ８８およびＣＤ４０ポリペプチドによるキメラ抗原受容体の共刺激 |
| EP3215522B1 (en) | 2014-11-03 | 2021-12-01 | Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum | T cell receptors directed against bob1 and uses thereof |
| AU2015342867B2 (en) * | 2014-11-06 | 2020-03-26 | University Of Maryland, Baltimore | CD8alpha and T cell receptor variants and methods of using same in modulating immune cell responses |
| AU2015362753A1 (en) * | 2014-12-15 | 2017-04-27 | Bellicum Pharmaceuticals, Inc. | Methods for controlled activation or elimination of therapeutic cells |
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| US20190008897A1 (en) * | 2015-07-22 | 2019-01-10 | University Of Washington | Compositions and methods for producing pro-inflammatory macrophages |
| KR20240132100A (ko) | 2015-07-28 | 2024-09-02 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 키메릭 항원 수용체를 발현하는 변형된 단핵세포/대식세포 및 그의 용도 |
| JP7171433B2 (ja) * | 2015-10-30 | 2022-11-15 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Ｈｅｒ－２発現固形腫瘍の処置のための組成物および方法 |
| JP6904667B2 (ja) | 2016-06-14 | 2021-07-21 | 日本光電工業株式会社 | バイトブロック及びガスセンサキット |
| WO2018077385A1 (en) * | 2016-10-25 | 2018-05-03 | Biontech Rna Pharmaceuticals Gmbh | Dose determination for immunotherapeutic agents |
| EP3621988A1 (en) | 2017-05-09 | 2020-03-18 | Bellicum Pharmaceuticals, Inc. | Methods to augment or alter signal transduction |
| JP7255895B2 (ja) | 2017-08-28 | 2023-04-11 | ボード オブ トラスティーズ オブ ミシガン ステイト ユニバーシティ | バクテリオファージおよびその変異体を使用したがんおよび感染を処置する組成物および方法 |
| SG11202002321YA (en) * | 2017-09-27 | 2020-04-29 | Univ Southern California | Novel platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy |
| US20200347148A1 (en) | 2017-12-08 | 2020-11-05 | Bellicum Pharmaceuticals, Inc. | Methods for enhancing and maintaining car-t cell efficacy |
| US20200308144A1 (en) | 2017-12-20 | 2020-10-01 | Bellicum Pharmaceuticals, Inc. | Multimeric piperidine derivatives |
| CA3120153A1 (en) * | 2018-11-20 | 2020-05-28 | Innovative Cellular Therapeutics Holdings, Ltd. | Modified cell expressing therapeutic agent and uses thereof |
| CA3149897A1 (en) | 2019-09-03 | 2021-03-11 | Daniel Getts | Methods and compositions for genomic integration |
| IL293718A (en) * | 2019-12-11 | 2022-08-01 | Myeloid Therapeutics Inc | Therapeutic cell compositions and methods for manufacture and uses thereof |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| KR20220125310A (ko) * | 2020-01-10 | 2022-09-14 | 코이뮨, 인크. | 종양 치료 방법 |
| EP4106819A1 (en) | 2020-02-21 | 2022-12-28 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| IL298693A (en) | 2020-06-04 | 2023-02-01 | Carisma Therapeutics Inc | New structures for chimeric antigen receptors |
| KR20230047361A (ko) | 2020-07-01 | 2023-04-07 | 아르스 파마슈티컬스 인크. | 항-asgr1 항체 접합체 및 이의 용도 |
| CA3197423A1 (en) | 2020-11-04 | 2022-05-12 | Daniel Getts | Engineered chimeric fusion protein compositions and methods of use thereof |
| EP4308133A4 (en) | 2021-03-17 | 2025-01-22 | Myeloid Therapeutics, Inc. | MANIPULATED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF |
| IL308445A (en) | 2021-05-11 | 2024-01-01 | Myeloid Therapeutics Inc | Methods and compositions for genomic integration |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050215472A1 (en) * | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
| EP2933334B1 (en) * | 2003-02-18 | 2019-09-18 | Baylor College of Medicine | Induced activation in dendritic cells |
| EP1687032B1 (en) * | 2003-11-14 | 2010-02-24 | Genvec, Inc. | Pharmaceutical composition for treating unresectable, locally advanced pancreatic cancer (lapc). |
| US8691210B2 (en) * | 2006-10-19 | 2014-04-08 | David M Spencer | Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptors and adaptors thereof |
| DK2224954T3 (en) * | 2007-11-07 | 2014-03-03 | Celldex Therapeutics Inc | Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) |
| US8114968B2 (en) * | 2008-03-03 | 2012-02-14 | Dyax Corp. | Metalloproteinase-12 specific monoclonal antibody |
| WO2009151503A2 (en) * | 2008-04-10 | 2009-12-17 | University Of Florida Research Foundation, Inc. | Compositions and methods for the treatment of a neoplasia |
| ES2633470T3 (es) * | 2008-09-22 | 2017-09-21 | Baylor College Of Medicine | Métodos y composiciones de generación de una respuesta inmune mediante la inducción de CD40 y adaptadores de receptores de reconocimiento de patrones |
-
2011
- 2011-04-14 WO PCT/US2011/032572 patent/WO2011130566A2/en not_active Ceased
- 2011-04-14 EP EP11769619.5A patent/EP2558109A4/en not_active Withdrawn
- 2011-04-14 JP JP2013505156A patent/JP5975983B2/ja active Active
- 2011-04-14 CA CA2795947A patent/CA2795947A1/en not_active Abandoned
- 2011-04-14 AU AU2011239569A patent/AU2011239569B2/en not_active Ceased
- 2011-04-14 US US13/087,329 patent/US20110287038A1/en not_active Abandoned
-
2013
- 2013-03-06 US US13/786,652 patent/US20140023647A1/en not_active Abandoned
-
2016
- 2016-03-24 JP JP2016060361A patent/JP2016117770A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013525305A5 (OSRAM) | ||
| Alnefaie et al. | Chimeric antigen receptor T-cells: an overview of concepts, applications, limitations, and proposed solutions | |
| Luo et al. | Progress and prospect of immunotherapy for triple-negative breast cancer | |
| EP3368689B1 (en) | Composition for modulating immune responses by use of immune cell gene signature | |
| CN112055695A (zh) | 用于基因表达的纳米粒子和其用途 | |
| Brunell et al. | Exhausted T cells hijacking the cancer-immunity cycle: Assets and liabilities | |
| CN115297868B (zh) | 用于编码核糖核酸的器官保护性表达和调节的组合物及方法 | |
| WO2017075465A1 (en) | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 | |
| US11788093B2 (en) | Chimeric antigen receptor t-cells expressing interleukin-8 receptor | |
| KR102741572B1 (ko) | 조직에서 코딩 리보핵산의 표적화된 전달, 발현 및 조절을 위한 조성물 및 방법 | |
| Yang et al. | Bispecific CD3-HAC carried by E1A-engineered mesenchymal stromal cells against metastatic breast cancer by blocking PD-L1 and activating T cells | |
| CN114786686A (zh) | Gold控制的转基因的联合疗法 | |
| Mai et al. | In vivo gene immunotherapy for cancer | |
| Lee et al. | Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models | |
| Wang et al. | Different evasion strategies in multiple myeloma | |
| WO2020168110A1 (en) | Ephb4-ephrin b2 receptor ligand pair as a novel marker for the treatment of prostate cancer | |
| Walters et al. | Modulating expression of inhibitory and stimulatory immune ‘checkpoints’ using nanoparticulate-assisted nucleic acid delivery | |
| KR20220092543A (ko) | 암의 치료를 위한 의약, 조합 의약, 의약 조성물, 면역 응답성 세포, 핵산 전달 비히클 및 제품 | |
| Snyder et al. | Good CARMA: Turning bad tumor‐resident myeloid cells good with chimeric antigen receptor macrophages | |
| Chekaoui et al. | Cancer vaccines: an update on recent achievements and prospects for cancer therapy | |
| Younis et al. | Understanding gene involvement in hepatocellular carcinoma: implications for gene therapy and personalized medicine | |
| Huang et al. | Facts and prospects of peptide in targeted therapy and immune regulation against triple-negative breast cancer | |
| Carreira et al. | Nanomedicines as multifunctional modulators of melanoma immune microenvironment | |
| US20240218019A1 (en) | Methods and compositions comprising mhc class i peptides | |
| Mokhtari et al. | The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy. Cancers. 2021; 13: 3596 |